Gyre Therapeutics (GYRE) EBT Margin (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly EBT Margin of 41.02% for Q1 2026, down 6203.0% year-over-year from 0.67% in Q1 2025, and down 23016.52% quarter-over-quarter from 0.18% in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) EBT Margin (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported EBT Margin for 16 consecutive years, with 41.02% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin fell 6203.0% year-over-year to 41.02%; the TTM figure through Mar 2026 stood at 0.48% (down 1479.0% YoY), while the FY2025 annual figure was 12.38%, down 957.0% from the prior year.
- EBT Margin retreated to 41.02% in Q1 2026 per GYRE's latest filing, from 0.18% in the prior quarter.
- Across five years, EBT Margin topped out at 45.93% in Q1 2024 and bottomed at 1830.73% in Q1 2022.
- Historically, EBT Margin has averaged 136.09% across 5 years, with a median of 15.42% in 2024.
- On a YoY basis, EBT Margin climbed as much as 185588 bps in 2023 and fell as far as 34691 bps in 2023.
- Gyre Therapeutics' EBT Margin stood at 22.46% in 2022, then plunged by 1544 bps to 369.38% in 2023, then jumped by 101 bps to 2.77% in 2024, then sank by 106 bps to 0.18% in 2025, then sank by 23017 bps to 41.02% in 2026.
- Business Quant data shows GYRE's EBT Margin at 41.02% in Q1 2026, 0.18% in Q4 2025, and 24.96% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | -49.59% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -49.59% |
| Mar 31, 2026 | -41.02% |
| Dec 31, 2025 | 13.78% |
| Sep 30, 2025 | 24.96% |
| Jun 30, 2025 | -5.30% |
| Mar 31, 2025 | 21.01% |
| Dec 31, 2024 | 2.77% |
| Sep 30, 2024 | 15.42% |
| Jun 30, 2024 | 23.92% |
| Mar 31, 2024 | 45.93% |
| Dec 31, 2023 | -369.38% |
| Sep 30, 2023 | 34.92% |
| Jun 30, 2023 | 19.96% |
| Mar 31, 2023 | 25.15% |
| Dec 31, 2022 | -22.46% |
| Mar 31, 2022 | -1,830.73% |
| Dec 31, 2021 | -832.34% |
| Sep 30, 2021 | -1,097.78% |
| Jun 30, 2021 | -1,759.45% |
| Mar 31, 2021 | -1,528.36% |